Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).

Recommended dosage: 960 mg orally once daily

500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter

Dose in combination with fulvestrant: 150 mg twice daily

600 mg every 3 weeks